Positive prelim results from SGN-35 against anaplastic large cell lymphoma

hodgkins-histopathology.jpg

Seattle Genetics is reporting positive preliminary results from a phase II trial of its promising anti-cancer drug brentuximab vedotin (SGN-35) against patients with anaplastic large cell lymphoma, (ALCL) …

Read more about this at CancerTreatment.net.

LymphomaInfo Social